BioSpace News Archive

The Nomination Committee prior to the 2022 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2021, and the Chairman of the Board.

Innovaccer Inc., the Health Cloud company, today announced it has been listed as a partner vendor of choice in the January 2022 Gartner® report, “Quick Answer: Use FHIR to Jump-Start Clinical Data Integration for U.S. Healthcare Payers.”

Cigna Corporation, a global health service company, announced that John Murabito, longtime Chief Human Resources Officer and current Chief Administrative Officer, will retire on April 1.

TransThera Sciences (Nanjing), Inc. (“TransThera”) announced that the U.S. Food and Drug Administration (“FDA”) approved the Investigational New Drug (“IND”) application of TT-01488, a non-covalent reversible Bruton’s Tyrosine Kinase (“BTK”) inhibitor, for the treatment of B-cell lymphomas on January 24, 2022, and TransThera will initiate the Phase I clinical trials in the U.S. soon.

Patients with moderately-to-severely active ulcerative colitis (UC) who took mirikizumab achieved statistically superior rates of clinical remission at 12 weeks compared to patients taking placebo in Eli Lilly and Company’s (NYSE: LLY) pivotal LUCENT-1 Phase 3 study.

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced preclinical data for SG-5-00455, the Company’s development candidate.

ANGLE plc, a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 6,667 new ordinary shares of £0.10 each in the Company.

US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Report Highlights.

Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028 Report Highlights.

Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, announces that the Company has issued new shares in the period from Friday, February 11, 2022 to Thursday, February 17, 2022 as a result of the utilization of the Company’s U.S. At-the-Market Offering Program with Cowen and Company, LLC (“Cowen”).